Rifaximin in Patients With Gastroesophageal Variceal Bleeding
Rifaximin in Patients With Gastroesophageal Variceal Bleeding
The purpose of the study is to evaluate the safety and efficacy of Rifaximin in the treatment
 of cirrhotic gastroesophageal variceal bleeding.
Gastroesophageal variceal bleeding is the most common and life-threatening condition in
 patients with portal hypertension, which are susceptibility to bacterial infection.

 However, the prophylaxis use of antibiotics remained uncertain and lack of high level
 evidences.
Inclusion Criteria:

 -  18 y.o. ≤age≤75 y.o.;

 -  Cirrhotic gastroesophageal variceal bleeding underwent endoscopic treatment (include
 esophageal varices ligation, endoscopic injection sclerosis and gastric N-
 butyl-cyanoacrylate injection).

 Exclusion Criteria:

 -  age <18 y.o. or age > 75 y.o.;

 -  Never had the variceal bleeding episode before;

 -  Do not have endoscopic treatment;

 -  Combined with other malignant tumors (not exclude patients with hepatocellular
 carcinoma who don't need treatment at the moment);

 -  Known infection after endoscopic treatment (Fever, microbial cultures positive, et
 al.)

 -  Massive ascites or combined with other high-risk factors that require prophylaxis use
 of antibiotics.

 -  Acute variceal bleeding within 5 days.

 -  Refuse to participate